# Assess Efficacy of of Oral Treprostinil in Patients With Symptomatic Primary or Secondary Raynaud's Phenomenon

> **NCT02583789** · EARLY_PHASE1 · COMPLETED · sponsor: **Brigham and Women's Hospital** · enrollment: 12 (actual)

## Conditions studied

- Raynaud's Phenomenon

## Interventions

- **DRUG:** oral treprostinil
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02583789
- **Lead sponsor:** Brigham and Women's Hospital
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-05
- **Primary completion:** 2021-12-31
- **Final completion:** 2021-12-31
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2022-01-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02583789

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02583789, "Assess Efficacy of of Oral Treprostinil in Patients With Symptomatic Primary or Secondary Raynaud's Phenomenon". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02583789. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*